Finance
Novo Nordisk Shares Plunge as Obesity Drug CagriSema Trails Eli Lilly in Clinical Trial
Shares of Novo Nordisk fell sharply on Monday after clinical trial results showed its experimental obesity drug, CagriSema, failed to outperform a rival product from Eli Lilly. The setback has triggered a broader sell-off in European healthcare stocks as investors reassess the competitive landscape of the lucrative weight-loss market.
February 23, 2026790 views
Score0
Enjoyed this story? Share it! 👇
Advertisement
Related Stories
Finance
Stellantis Records First Annual Loss in History Following 20 Billion Euro EV Writedown
1d ago
Finance
Imperial Petroleum Accelerates Fleet Expansion as Valuation Multiples Lag Behind Earnings
1d ago
Finance
Syngenta Prepares $10 Billion Hong Kong IPO for Second Quarter Launch
1d ago
Finance
Uber and Lyft Shares Surge as Trump Administration Scraps Independent Contractor Rule
1d ago
Comments (0)
Sign in to leave a comment.
No comments yet. Be the first to share your thoughts!